On 22 January 2025, PMLive reported that the UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Imfinzi® (durvalumab) in combination with chemotherapy (etoposide) plus either carboplatin or cisplatin for the treatment of adults with untreated extensive-stage small cell lung cancer (SCLC).
This follows positive recommendation by Australia’s Pharmaceutical Benefits Assessment Committee (PBAC) for Imfinzi® in combination with platinum-based chemotherapy for the treatment of deficient mismatch repair (dMMR) endometrial cancer (December 2024). Imfinzi® is also currently under review by Australia’s Therapeutic Goods Administration for the treatment of patients with limited-stage small cell lung cancer.
In December 2024, the US FDA granted Priority Review of AstraZeneca’s sBLA for Imfinzi® for the treatment of patients with muscle-invasive bladder cancer (MIBC).